

Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). It can spread through contact with infected body fluids like blood, saliva, vaginal fluids and semen. It can also be passed from a mother to her baby during childbirth.
HBsAg is a protein on the surface of HBV that can be detected in high levels in serum during acute or chronic HBV infection. This antigen can be found in your blood within several weeks after the infection starts and therefore serves as one of the earliest markers of a hepatitis B infection. Most infected individuals do not exhibit any symptoms following initial infection. However, some common symptoms are fever, nausea, vomiting, loss of appetite, stomach pain, joint pain, dark-colored urine, light-colored stool, and the yellowing of skin and eyes (jaundice). The test provides an HBsAg - Quantitative measurement and the corresponding HBsAg Value, which helps assess the amount of hepatitis B surface antigen present in the blood.
The Hepatitis B s (Surface) Antigen Quantitative test measures the amount of hepatitis B surface antigen present in the blood. It is commonly used in individuals with chronic Hepatitis B infection to assess disease activity, monitor response to treatment, and help evaluate the likelihood of long-term viral control.
This test may be recommended at the time of diagnosis and during follow-up visits, particularly in individuals receiving antiviral therapy. Changes in HBsAg levels over time can provide valuable information about how the infection is progressing and whether treatment is helping to reduce viral activity.
However, the quantitative HBsAg is not a direct measure of viral load. The test is often interpreted along with other crucial investigations such as HBV DNA (viral load), liver function tests, and other hepatitis B serology markers for diagnosis and monitoring.
A decline in HBsAg levels over time may indicate improved immune control of the infection or a favorable response to treatment. Persistently high HBsAg levels may be associated with ongoing viral activity and can help identify individuals who may require closer monitoring. The results of this test assist healthcare providers in assessing disease status, monitoring treatment response, and making decisions regarding long-term management of chronic Hepatitis B.
No special preparation is needed for this test. You may eat and drink as per your daily routine. It is preferred to provide a clinical history. However, inform the doctor about any medications that you are taking or if you have a history of any bleeding disorders or recent vaccinations, as these factors may influence the test results.
Lab test results may vary across laboratories. Abnormal test results require an expert interpretation; therefore, don't self-medicate at home solely based on these results, and always consult a doctor for a proper understanding of the test results.
The Hepatitis B s (Surface) Antigen Quantitative test measures the amount of a specific protein on the surface of the Hepatitis B virus (HBV) in the bloodstream. This protein, HBsAg, serves as a crucial marker for identifying HBV infection and its presence in high levels indicates active viral replication. By quantifying the amount of HBsAg, this test helps determine the viral load, which is crucial for evaluating the extent of the infection and the patient’s infectivity. The Hepatitis B s (Surface) Antigen Quantitative test is essential for monitoring the effectiveness of treatments such as antiviral therapy, and for implementing measures to prevent the spread of Hepatitis B virus to others.
The Hepatitis B s (Surface) Antigen Quantitative test is done:
- To diagnose current and past infection with Hepatitis B virus (HBV).
- To quantify the level of HBsAg in the blood to assess the severity of HBV infection.
- To screen individuals at higher risk of HBV infection such as healthcare workers, before an operative procedure etc.
- To facilitate prevention of HBV transmission to others, especially newborns or transplant recipients
- To monitor the effectiveness of antiviral therapy in individuals with chronic Hepatitis B.
- Clinical history is preferred.























